

RESULTS

Outcome of patients

This study included 36 patients admitted to the CCU for treatment of acute attack of SVT. the 36 patients were randomized into two groups. verapamil group & magnesium sulfate group.

Effects of verapamil & magnesium sulfate on conversion of SVT to normal sinus rhythm.

A) Verapamil group:

This group included 18 patients (7 females & 11 males) with mean age 37.388 ± 10.204 years. Two patients with MVP & 16 patient without underlying heart disease.

All patients recieved dose A 13 out of 18 patients reverted to normal sinus rhythm which increased to 16 patients after dose B after 15 minutes of dose A, the effective dose of verapamil wase 5.2 ± 1.8 mg.

Five patients failed to be reverted to normal sinus rhythm .the first patient was male 35 years old 65 KG with SVT pulse rate 180 bests/m .The second patient was male 44 years old 55 KG with SVT heart rate 190 beats/m. the third patient was female 30 years old 60 KG with SVT heart rate 190 b m. they recieved average 4.4 mg verapamil as a dose A but the heart rate not

changed after 15 minutes elapsed , so they recieved dose B (10 mg)and after 5 minutes they were reverted to normal sinus rhythm ,but they developed hypotension , (90/60) , (90/55), (90/60) respectively,they recieved intravenouse fluids &they were put on the trendelenberge posision .The fourth&fifth patient failed to reverted to normal sinus rhythm after dose B so they recieved synchronized D.C shock .

The fourth was female 40years old,55 Kg she recieved(4.1mg) verapamil as a dose A & after 15 minutes the heart rate chaged from 180 to 160 beats/m , so she recieved dose B (8,25mg) verapamil & after 15 minutes the heart rate was still 160 beats /m . S0 synchronized D.C shock was applied .The fifth was male 37 years ,70 KG, he recieved (5,25mg)verapamil as a dose A&after 15 minutes the heart rate changed from 200 b/m to 150 b/m so he recieved dose B (10.5mg)verapamil but after 15 minutes elapsed the heart rate was still 150 b/m so synchronised D.C shock was applied. The overall outcome of this group was 16 out of 18 patients reverted to normal sinus rhythm(88.88%).

B) Magnesium sulfate group:

This group included 18 patients (10 females &8 males)with mean age 38.6 ± 10.56 years.One patient with MVP &one patient with

old myocardial infarction & 16 patients without underlying heart disease. All patients received dose A 15 out of 18 patients reverted to normal sinus rhythm which increased to 17 patients after dose B after 15 minutes of dose A, the effective dose of magnesium was 2 gm.

Three patients failed to revert to normal sinus rhythm, the first patient was male 20 years old 75 KG with SVT pulse rate 175 beats/m. The second patient was male 60 years old 60 KG with SVT heart rate 140 beats/m, both of them received two grams of magnesium sulfate followed by 10 ml flush of normal saline as a dose A but the heart rate not changed after 10 minutes elapsed so they received dose B (two grams of $MgSO_4$) and after 5 minutes the heart rate reverted to normal sinus rhythm. The third patient failed to revert to normal sinus rhythm after dose B so he received synchronized D.C shock.

He was male 38 years old. 80 Kg with SVT. heart rate 180 beats/m not changed after dose A & dose B. The overall outcome of this group was 17 out of 18 patients were reverted to normal sinus rhythm (94.44%).

Table NO (3) compares between verapamil&magnesium group as regard all clinical data studied, from the table there's no significant difference between both

groups as regard all data except:

- Pulse rate after treatment which was significant high in magnesium group
- Systolic blood pressure drop which was significant in verapamil group , see figure (6).
- Pulse drop which was significant in magnesium group , see figure (14).

TABLE NO(3)

Data		Mean	+ SD	t-Test	P-Value	Significance
age	verap.G	37.3	10.20	-.3692	>0.05	not signif
	mgso ₄ .G	38.6	10.56			
wt	verap.G	70.466	8.27	-1.697	>0.05	not signif
	mgso ₄ .G	75.80	8.92			
SBP (B)	verap.G	124.16	11.91	.6312	>0.05	not signif
	mgso ₄ .G	121.83	10.199			
DBP(B)	verap.G	80.000	9.39	-.5000	>0.05	not signif
	mgso ₄ .G	80.000	7.859			
SBP(A)	verap.G	113.38	16.740	-.7982	>0.05	not signif
	mgso ₄ .G	116.94	8.768			
DBP(A)	verap.G	72.777	9.2708	-1.157	>0.05	not signif
	mgso ₄ .G	76.111	7.962			
pulse(B)	verap.G	171.11	19.85	-.1594	>0.05	not signif
	mgso ₄ .G	172.11	17.739			
pulse(A)	verap.G	97.8	19.48	-3.389	<0.001	highly signif
	mgso ₄ .G	119.53	18.96			
E.F	verap.G	64.26	5.08	.876	>0.05	not signif
	mgso ₄ .G	62.80	8.05			
SBP (drop)	verap.G	10.77	11.33	1.899	<0.05	signif
	mgso ₄ .G	4.72	7.37			
DBP (drop)	verap.G	7.222	9.27	1.114	>0.05	not signif
	mgso ₄ .G	3.888	8.66			
pulse (drop)	verap.G	73.53	21.56	2.94	>0.05	signif
	mgso ₄ .G	52.33	21.81			

A - after

B - before

A comparison of before & after treatment as regard the various parameters studied in each group was done:

from these comparison in the verapamil group there was :

- highly significant difference drop in systolic blood pressure, see table no(4) & see figure no(6).
- significant difference drop in diastolic blood pressure, see table no (5) & see figure no (7).
- highly significant difference drop in pulse, see table no (6) & see figure no (8).

In the magnesium sulfate group there was :

- significant difference drop in systolic blood pressure, see table no (7) & see figure no (9).
- significant difference drop in diastolic blood pressure, see table no (8) & see figure no (10)
- highly significant difference drop in pulse see table no (9) & see figure no (11)

*Verapamil group**TABLE NO(4) systolic blood pressure*

	mean	\pm S D	T test	P value	sig
Before	124,166	\pm 11,9127	4,0332	<0,001	HIGH
After	113,3889	\pm 16,7407			SIGNIF

*see figure(6)**TABLE NO (5) diastolic blood pressure*

	mean	\pm S D	T test	P value	sig
Before	80,000	\pm 9,393	3,3051	<,05	SIGNIF
After	72,7778	\pm 9,2708			

*see figure(7)**TABLE NO (6) pulse*

	mean	\pm S D	T test	P value	sig
Before	171,111	\pm 19,8521	14.7615	<,001	HIGH
After	97,8889	\pm 19,484			SIGNIF

see figure(8)

magnesium group

TABLE NO(7) systolic blood pressure

	mean	\pm S D	T test	P value	sig
Before	121,8333	\pm 10,1995	2.7978	<,05	SIGNIF
After	116,9444	\pm 8,7681			

see figure(9)

TABLE NO (8) diastolic blood pressure

	mean	\pm S D	T test	P value	sig
Before	80,000	\pm 7,8591	1,9031	<,05	SIGNIF
After	76,1111	\pm 9,2708			

see figure(10)

TABLE NO(9) pulse

	mean	\pm S D	T test	P value	sig
Before	172,111	\pm 17,7396	10,4873	.001	HIGH SIGNIF
After	119,6111	\pm 18,9679			

see figure(11)

chi square test to compare between different groups see table NO(10).

when we compare the response of patients to treatment after dose A and dose B & number of patients who are not respond either to dose A or dose B in each group we found that there was no significant difference between both groups

TABLE NO (10).

group	dose A	dose B	not respond	TOTAL
verapamil group	13	3	2	18
Mgso4 group	15	2	1	18
TOTAL	28	5	3	36

$$p > 0,05 = \text{not sig.}$$

COMPARISON AS REGARD THE TIME OF CONVERSION

TABLE NO (11)

GROUP	MEAN	S.D	RANG
verapamil	106,66 second	$\pm 21,14$	80-150 second
magnesium	29,33 second	$\pm 6,06$	20-40 second

T = 12,17 P = 0,01 highly significant for magnesium.

CORRELATION WITH LEFT VENTRICULAR EJECTION FRACTION

- The correlation was done between the pulse drop and left ventricular ejection fraction in the verapamil group revealed
- A non significant positive correlation with ejection fraction .. as shown on table NO(12) &Figure NO(15)&NO(16).

Table (12) correlation between pulse drop & ejection fraction

parameters data	" r "	sig
Ejection fraction	,0465	not significant

critical value = +/- 0,466


- correlation was done between the pulse drop and left ventricular ejection fraction in the magnesium group revealed .
- A non significant positive correlation with ejection fraction as shown in table NO (13) &Figure NO(15)&NO(17)

Table (13) correlation between pulse drop &ejection fraction

parameters	" r "	sig
E . F	,1806	not significant


critical value - - ,46

Fig. (5): Mean SBP before and after verapamil intake




($P < 0.001 = \text{HS}$)

Fig. (7): Mean DBP before and after verapamil intake




($P < 0.05 = S$)

Fig. (8): Mean pulse rate before and after verapamil intake




($P < 0.001 = \text{HS}$)

Fig. (9): Mean SBP before and after MgSO₄ intake




($P < 0.05 = S$)

Fig. (10): Mean DBP before and after MgSO₄ intake




($P < 0.05 = S$)

Fig- (n) : Mean pulse rate before and after MgSO₄ intake




($P < 0.001 = \text{HS}$)

Fig. (12): Mean drop in SBP in both verapamil and MgSO₄ treated groups




($P < 0.05 = S$)

Fig. (2) = Mean drop in DBP in both verapamil and MgSO₄ treated groups




($P > 0.05 = \text{NS}$)

Fig. (17): Mean drop in pulse rate in both verapamil and MgSO₄ treated groups



($P < 0.05 = S$)

Fig. (15): Mean Ejection Fraction (EF) in both verapamil and MgSO₄ treated groups



($P > 0.05 = \text{NS}$)

Ejection fraction
76




Fig. (16): Correlation between ejection fraction and pulse drop in verapamil cases

REGRESSION EQUATION (Shown by +'s on scatterplot):

INTERCEPT= 63.44122074319
SLOPE= 1.2942357073283E-02

$r = .0465$
($P > 0.05 = NS$)




Fig. 47: Correlation between ejection fraction and pulse drop in MgSO₄ cases

REGRESSION EQUATION (Shown by +'s on scatterplot):

INTERCEPT= 58.739084132055

SLOPE= 6.8461889548149E-02

$r = .1806$

($P > 0.05 = NS$)